U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2011
587
Name Type Language
BELIMUMAB
DASH   EMA EPAR   INN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
BELIMUMAB [PURPLE BOOK CDER]
Common Name English
BELIMUMAB [MART.]
Common Name English
GSK-1550188
Code English
HGS1006
Code English
LYMPHOSTAT-B
Brand Name English
BELIMUMAB [MI]
Common Name English
BELIMUMAB (GENETICAL RECOMBINATION) [JAN]
Common Name English
BELIMUMAB [JAN]
Common Name English
BELIMUMAB [USAN]
Common Name English
HGS-1006
Code English
BEL-114333
Code English
belimumab [INN]
Common Name English
BELIMUMAB [VANDF]
Common Name English
BELIMUMAB [EMA EPAR]
Common Name English
GSK1550188
Code English
BELIMUMAB (GENETICAL RECOMBINATION)
JAN  
Common Name English
IMMUNOGLOBULIN G1, ANTI (HUMAN CYTOKINE BAFF) (HUMAN MONOCLONAL LYMPHOSTAT-B HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL LYMPHOSTAT-B .LAMBDA. CHAIN, DIMER
Common Name English
BENLYSTA
Brand Name English
BEL114333
Code English
Belimumab [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-ATC L04AA26
Created by admin on Sat Dec 16 16:32:36 GMT 2023 , Edited by admin on Sat Dec 16 16:32:36 GMT 2023
NDF-RT N0000182637
Created by admin on Sat Dec 16 16:32:36 GMT 2023 , Edited by admin on Sat Dec 16 16:32:36 GMT 2023
FDA ORPHAN DRUG 921522
Created by admin on Sat Dec 16 16:32:36 GMT 2023 , Edited by admin on Sat Dec 16 16:32:36 GMT 2023
NCI_THESAURUS C20401
Created by admin on Sat Dec 16 16:32:36 GMT 2023 , Edited by admin on Sat Dec 16 16:32:36 GMT 2023
WHO-VATC QL04AA26
Created by admin on Sat Dec 16 16:32:36 GMT 2023 , Edited by admin on Sat Dec 16 16:32:36 GMT 2023
EMA ASSESSMENT REPORTS BENLYSTA (AUTHORIZED LUPUS ERYTHEMSTOSUS, SYSTEMIC)
Created by admin on Sat Dec 16 16:32:36 GMT 2023 , Edited by admin on Sat Dec 16 16:32:36 GMT 2023
Code System Code Type Description
DRUG CENTRAL
4949
Created by admin on Sat Dec 16 16:32:36 GMT 2023 , Edited by admin on Sat Dec 16 16:32:36 GMT 2023
PRIMARY
USAN
OO-56
Created by admin on Sat Dec 16 16:32:36 GMT 2023 , Edited by admin on Sat Dec 16 16:32:36 GMT 2023
PRIMARY
WIKIPEDIA
BELIMUMAB
Created by admin on Sat Dec 16 16:32:36 GMT 2023 , Edited by admin on Sat Dec 16 16:32:36 GMT 2023
PRIMARY
IUPHAR
6887
Created by admin on Sat Dec 16 16:32:36 GMT 2023 , Edited by admin on Sat Dec 16 16:32:36 GMT 2023
PRIMARY
DAILYMED
73B0K5S26A
Created by admin on Sat Dec 16 16:32:36 GMT 2023 , Edited by admin on Sat Dec 16 16:32:36 GMT 2023
PRIMARY
FDA UNII
73B0K5S26A
Created by admin on Sat Dec 16 16:32:36 GMT 2023 , Edited by admin on Sat Dec 16 16:32:36 GMT 2023
PRIMARY
NDF-RT
N0000182156
Created by admin on Sat Dec 16 16:32:36 GMT 2023 , Edited by admin on Sat Dec 16 16:32:36 GMT 2023
PRIMARY Decreased B Lymphocyte Activation [PE]
ChEMBL
CHEMBL1789843
Created by admin on Sat Dec 16 16:32:36 GMT 2023 , Edited by admin on Sat Dec 16 16:32:36 GMT 2023
PRIMARY
CAS
356547-88-1
Created by admin on Sat Dec 16 16:32:36 GMT 2023 , Edited by admin on Sat Dec 16 16:32:36 GMT 2023
PRIMARY
SMS_ID
100000090056
Created by admin on Sat Dec 16 16:32:36 GMT 2023 , Edited by admin on Sat Dec 16 16:32:36 GMT 2023
PRIMARY
RXCUI
1092437
Created by admin on Sat Dec 16 16:32:36 GMT 2023 , Edited by admin on Sat Dec 16 16:32:36 GMT 2023
PRIMARY RxNorm
NDF-RT
N0000182636
Created by admin on Sat Dec 16 16:32:36 GMT 2023 , Edited by admin on Sat Dec 16 16:32:36 GMT 2023
PRIMARY B Lymphocyte Stimulator-directed Antibody Interactions [MoA]
EVMPD
SUB25607
Created by admin on Sat Dec 16 16:32:36 GMT 2023 , Edited by admin on Sat Dec 16 16:32:36 GMT 2023
PRIMARY
MERCK INDEX
m2294
Created by admin on Sat Dec 16 16:32:36 GMT 2023 , Edited by admin on Sat Dec 16 16:32:36 GMT 2023
PRIMARY Merck Index
INN
8381
Created by admin on Sat Dec 16 16:32:36 GMT 2023 , Edited by admin on Sat Dec 16 16:32:36 GMT 2023
PRIMARY
DRUG BANK
DB08879
Created by admin on Sat Dec 16 16:32:36 GMT 2023 , Edited by admin on Sat Dec 16 16:32:36 GMT 2023
PRIMARY
NCI_THESAURUS
C91385
Created by admin on Sat Dec 16 16:32:36 GMT 2023 , Edited by admin on Sat Dec 16 16:32:36 GMT 2023
PRIMARY
LACTMED
Belimumab
Created by admin on Sat Dec 16 16:32:36 GMT 2023 , Edited by admin on Sat Dec 16 16:32:36 GMT 2023
PRIMARY
ACTIVE MOIETY
BELIMUMAB
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966